1. Prostaglandin E1 administration for prevention of contrast-induced acute kidney injury
- Author
-
Geng, Ning, Zou, Deling, Chen, Yanli, Ren, Li, Xu, Lisheng, Pang, Wenyue, and Sun, Yingxian
- Subjects
Male ,nephroprotection ,Incidence ,Contrast Media ,Acute Kidney Injury ,Treatment Outcome ,Creatinine ,Humans ,angiography ,Female ,Alprostadil ,Systematic Review and Meta-Analysis ,Research Article ,Randomized Controlled Trials as Topic - Abstract
Background: PGE1 has been studied for prevention of CI-AKI in several RCTs and significant heterogeneous results exist. Methods: We searched PubMed, EMBase, and Cochrane Central Register of Controlled Trials up to December 26, 2017 for RCTs comparing PGE1 with placebo or other active medications for the prevention of CI-AKI in patients. Odds ratio and 95% confidence interval (CI) were used for pooling dichotomous data, while mean difference and 95% confidence interval for pooling continuous data. Results: Seven RCTs involving 1760 patients were included in this meta-analysis. All these 7 trials reported the incidence of CI-AKI and compared with placebo or other treatment options, PGE1 was associated with a reduced risk of CI-AKI (OR: 0.38, 95% CI: 0.28–0.53; P
- Published
- 2018